Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 34, Supplement 1, pp S127–S133 | Cite as

Teniposide: overview of its therapeutic potential in adult cancers

  • Franco M. Muggia
Session 3: Clinical Trials and Applications Teniposide, Solid Tumors, Epipodophyllotoxin

Abstract

Teniposide was introduced into clinical trials prior to etoposide, but its role was not defined because interest shifted early on to etoposide. However, long-term encouraging results obtained in acute leukemia treated with teniposide have rekindled interest in this compound. In addition to pharmacokinetic differences, teniposide has greater CNS penetrance and is more lipophilic. Its greater potency is related to enhanced intracellular uptake. Although its antitumor spectrum of activity appears to be very similar to that of etoposide, a search for some differences might prove instructive.

Key words

Teniposide Solid tumors Epipodophyllotoxin 

References

  1. 1.
    Beck WT (1989) Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 81: 1683Google Scholar
  2. 2.
    Bhuchar VK, Boyle LE, Lanzotti VJ (1978) VM-26 in non-oat cell bronchogenic carcinoma (abstract C-404). Proc Am Assoc Cancer Res/Proc Am Soc Clin Oncol 19: 407Google Scholar
  3. 3.
    Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH (1986) Teniposide (VM-26) an overlooked highly active agent in small-cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 4: 525Google Scholar
  4. 4.
    Bork E, Ersball J, Dombernowsky P, Bergman B, Hansen M, Hansen HH (1991) Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 9: 1627Google Scholar
  5. 5.
    Burg MEI van der, Ten Bokkel Huinink WW, Vriesendorp R, Van Oosterom RT, Neijt JP, Vermoken JB, van Putten WL, Kooiman A (1987) Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netheralands Joint Study Group for Ovarian Cancer. Eur J Cancer Clin Oncol 23: 997Google Scholar
  6. 6.
    Cerny T, Pedrazzini A, Joss RA, Brunner KW (1988) Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). Eur J Cancer Clin Oncol 24: 1791Google Scholar
  7. 7.
    Chakravorty RC, Serkar AK, Sen S, Mukerji B (1967) Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report. Br J Cancer 21: 33Google Scholar
  8. 8.
    Chiuten DF, Bennett JM, Creech RH, Glick J, Falkson G, Brodovsky HS, Begg CB, Muggia FM, Carbone P (1979) VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group study (EST 1474). Cancer Treat Rep 63: 7Google Scholar
  9. 9.
    Clark PI (1992) Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin Oncol 19 [Suppl 6]: 20Google Scholar
  10. 10.
    Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, Woll J (1984) Phase II study of PALA, amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST 2579). Cancer Treat Rep 68: 1183Google Scholar
  11. 11.
    deVries EGE, Mulder NH, Postmus PE, Vriesendorp R, Villemse PH, Sleijfer DT (1986) High dose teniposide for refractory malignancies: a phase I study. Cancer Treat Rep 70: 595Google Scholar
  12. 12.
    Dombernowsky P, Nissen NI, Larsen V (1972) Clinical investigation of a new podophyllin derivative, VM 26, in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 5: 71Google Scholar
  13. 13.
    European Organization for Research on the Treatment of Cancer (1972) Cooperative Group for Leukaemias and Haematosarcomas: clinical screening of epipodophyllotoxin VM-26 in malignant lymphomas and solid tumors. BMJ 2: 744Google Scholar
  14. 14.
    Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A (1988) Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6: 1264Google Scholar
  15. 15.
    Glisson BS, Sullivan DM, Gupta R, Ross WE (1987) Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr 4: 89Google Scholar
  16. 16.
    Goldman ID, Yalowich JC (1984) Effects of epipodophyllotoxins on membrane transport and transport-dependent intracellular processes in the Ehrlich ascites tumor: enhancement of transport and metabolism of methotrexate; inhibition of thymidine transport and metabolism. In: Issell BF, Muggia FM, Carter SK (eds) Etoposide (VP-16): current status and new developments. Academic Press, New York, p 87Google Scholar
  17. 17.
    Greenspan EM, Colsky J, Schoenbach B, Shear MJ (1954) Response of patients with advanced neoplasms to the intravenous administration of alpha-peltatin. J Natl Cancer Inst 14: 1257Google Scholar
  18. 18.
    Grossberg H, Opfell R, Glick J, Bakemeier R, Schnetzer G III, Muggia F (1987) Treatment of advanced refractory lymphoma with teniposide and lomustine. Cancer Treat Rep 71: 215Google Scholar
  19. 19.
    Gutin PH, Walker MD (1977) IV methyl-CCNU, VM26 and cranial irradiation in therapy for malignant brain tumors. Cancer Treat Rep 61: 1715Google Scholar
  20. 20.
    Holoye PY, Winn RJ, Craig K, Goodwin W, Wade J, Cammon MW (1989) Phase II study of teniposide in small cell bronchogenic carcinoma (abstract 946). Proc Am Soc Clin Oncol 8: 243Google Scholar
  21. 21.
    Howell SB, Hom D, Sanga R, Vick JS, Abramson IS (1989) Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole. Cancer Res 49: 3178Google Scholar
  22. 22.
    Issell BF, Muggia FM, Carter SK (eds) (1984) Etoposide (VP-16): current status and new developments. Academic Press, New York p 355Google Scholar
  23. 23.
    Jacobs P (1985) The epipodophyllotoxin VP-16-213 in combination chemotherapy for adults with acute non-lymphoblastic leukemia. Hamatol Bluttransfus 29: 70Google Scholar
  24. 24.
    Jankowski RP, Vahrson H (1977) Die Toxizität hoher Dosen von VM26 (4-Demethyl-epipodophyllotoxin-β-D-thenylidene glucoside). Med Klin 72: 122Google Scholar
  25. 25.
    Kelly MG, Hartwell JL (1954) The biological effects and chemical composition of podophyllin. A review. J Natl Cancer Inst 14: 967Google Scholar
  26. 26.
    Kerrigan D, Pommier Y, Kohn KW (1987) Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT 29 cell lines: relationship to cytotoxicity. NCI Monogr 4: 123Google Scholar
  27. 27.
    Laubenstein LJ, Krigel RL, Odajnik CM, Hymes KB, Freidman KA, Wernz JC, Muggia FM (1984) Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 2: 1115Google Scholar
  28. 28.
    Lee T, Roberts D (1983) Uptake as a determinant of resistance to teniposide (VM-26). Fed Proc 42: 768Google Scholar
  29. 29.
    Loike JD, Horwitz SB (1976) Effect of VP 16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15: 55443Google Scholar
  30. 30.
    Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB (1978) Structure-activity of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res 38: 2688Google Scholar
  31. 31.
    Long BH (1991) Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin Oncol 18 [Suppl 4]: 3Google Scholar
  32. 32.
    Long BH, Minocha A (1983) Inhibition of topoisomerase II by VP 16-213 (etoposide), VM 26 (teniposide), and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Assoc Cancer Res 24: 321Google Scholar
  33. 33.
    Mathe G, Schwartzenberg L, Pouillart P, Oldham R, Weiner R, Jasmin C, Rosenfeld C, Hayat M, Misset JL, Musset M, Schneider M, Amiel JL, DeVassal F (1974) Two epipodophyllotoxin derivatives, VM26 and VP 16213, in the treatment of leukemia, hematosarcomas, and lymphomas. Cancer 34: 985Google Scholar
  34. 34.
    Muggia FM, Kelley SL (1992) Teniposide in adult solid tumors: a historical perspective. Semin Oncol 19 [Suppl 6]: 43Google Scholar
  35. 35.
    Muggia FM, Russell CA (1991) New chemotherapies for ovarian cancer: systemic and intraperitoneal podophyllotoxins. Cancer 67 [Suppl 1]: 225Google Scholar
  36. 36.
    Muggia FM, Selawry OS, Hansen HH (1971) Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-β-D-glucopyranoside) (NSC-122819). Cancer Chemother Rep 55: 575Google Scholar
  37. 37.
    Muss H, Bundy BN, Yazigi R, Yordan E (1987) Teniposide in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 71: 873Google Scholar
  38. 38.
    Newlands ES, Bagshawe KD (1977) Epipodophyllin derivative (VP16-213) in malignant teratomas and choriocarcinomas. Lancet II: 87Google Scholar
  39. 39.
    Pedersen AG, Hansen HH (1983) Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev 10: 245Google Scholar
  40. 40.
    rodman JH, Abromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evans WE (1985) Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 5: 1007Google Scholar
  41. 41.
    Ross WE, Rowe T, Glisson B, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857Google Scholar
  42. 42.
    Rowe T, Kupfer G, Ross W (1985) Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 34: 2483Google Scholar
  43. 43.
    Rozencweig M, Von Hoff DD, Henney J, Muggia FM (1977) VM-26 and VP 16-213: a comparative analysis. Cancer 40: 334–342Google Scholar
  44. 44.
    Ryan DH, Kopecky KJ, Head D, Gumbert CN, Grever MR, Karanaes C, Weick JK, Coltman CA Jr (1987) Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group study. Cancer Treat Rep 71: 713Google Scholar
  45. 45.
    Samson MK, Baker LH, Talley RW, Fraile RJ (1978) VM26 (NCS-122819): a clinical study in advanced cancer of the lung and ovary. Eur J Cancer 14: 1395Google Scholar
  46. 46.
    Sanz GF, Sanz MA, Rafecas FJ, Martinez JA, Martin-Aragones G, Marty ML (1986) Teniposide and cytarabine: combination chemotherapy in the treatment of relapsed adolescent and adult acute lymphoblastic leukemia. Cancer Treat Rep 70: 1321Google Scholar
  47. 47.
    Schwartsmann G, Sprinz E, Kronfeld M, Vinholes J, Sander E, Zampese M, Preger R, Klakun L, Brunetto AL (1991) Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. Eur J Cancer 27: 1637Google Scholar
  48. 48.
    Sessa C, D'Incalci M, Landoni F, Rossi C, Urso R (1986) Teniposide in refractory ovarian cancer: a phase II study. Cancer Treat Rep 68: 815Google Scholar
  49. 49.
    Sinha BK, Eliot HM, Kalayanaraman B (1988) Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett 227: 240Google Scholar
  50. 50.
    Sklansky BD, Mann-Kaplan RS, Reynolds AF, Rosenblum ML, Walker MD (1974) 4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460Google Scholar
  51. 51.
    Slevin ML, Clark PI, Joel SP, Osborne WM, Gregory WM, Lowe RH, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333Google Scholar
  52. 52.
    Sörensen JB, Bach F, Dombernowsky P, Hansen HH (1991) Phase II study of teniposide in adenocarcinoma of the lung. Cancer Chemother Pharmacol 27: 487Google Scholar
  53. 53.
    Sonneveld P (1992) Teniposide in lymphomas and leukemias. Semin Oncol 19 [Suppl 6]: 59Google Scholar
  54. 54.
    Sonntag RW, Senn HJ, Nagel G, Giger K, Alberto P (1974) Experience with 4′-demethyl epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis. Eur J Cancer 10: 93Google Scholar
  55. 55.
    Stähelin HF, Wartburg A von (1991) The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 51: 5Google Scholar
  56. 56.
    Stoter G, Oosterom AT van, Mulder JH, dePauw M, Fossa SD (1984) Combinaton chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 20: 315Google Scholar
  57. 57.
    Sullivan DM, Chow K-C, Glisson BS, Ross WE (1987) Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monog 4: 73Google Scholar
  58. 58.
    Tirelli U, Carbone A, Franchini G, Galligioni E, Veronesi A, Trovo MG, Volpe R, Tumolo S, Grigoletto E (1982) VM26 in malignant hematological diseases: a phase II study. Cancer Chemother Pharmacol 7: 173Google Scholar
  59. 59.
    Trempe G, Sykes M, Young C, Krakoff I (1970) Phase I trial of the podophyllotoxin derivative VM-26. Proc Am Assoc Cancer Res 11: 79Google Scholar
  60. 60.
    Vaitkevicius VK, Reed ML (1966) Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076). Cancer Chemother Rep 50: 565Google Scholar
  61. 61.
    Warrell RP Jr, Straus DJ, Young CW (1982) Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26). Cancer Treat Rep 66: 1121Google Scholar
  62. 62.
    Woods RL, Fox RM, Tattersall MHN (1979) Treatment of small cell bronchogenic carcinoma with VM-26. Cancer Treat Rep 63: 2011Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Franco M. Muggia
    • 1
  1. 1.University of Southern CaliforniaNorris Cancer CenterLos AngelesUSA

Personalised recommendations